Project Grant HT94252510852
Award Date 10/1/25
Completion Date 9/30/28
Dollars Obligated $490K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,348,314.00 to The University of Texas MD Anderson Cancer Center to conduct research on building T-cell products for neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors (NF1-associated MPNST) through antigen discovery and epigenome targeting. The research aims to transform healthcare for military service members, veterans, and the...
- This $1,431,215.00 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Texas M.D. Anderson Cancer Center in Houston, TX. The grant is focused on building T-cell products to target malignant peripheral nerve sheath tumors (MPNSTs) associated with neurofibromatosis type 1 (NF1). The research aims to advance antigen discovery and epigenome targeting approaches to develop novel...
- The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...
- The University of Texas MD Anderson Cancer Center received a $1,041,605 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research titled "INTERROGATING TUMOR-IMMUNE-NEURON CROSS TALK AT SINGLE-CELL RESOLUTION IN A PANEL OF NOVEL SOMATIC TRANSGENIC NF1 TUMOR MODELS". This 3-year award, starting on September 1, 2023, will support basic and translational cancer research focused on understanding the interactions...
- This $414,472 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The University of Texas M.D. Anderson Cancer Center to investigate neuronal mimicry in the treatment of SMARCB1-deficient renal medullary carcinoma. The 3-year award, effective from September 1, 2025 through August 31, 2028, will fund advanced biomedical research aimed at transforming healthcare for military service members,...
- The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
- This $505,071 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the University of Texas MD Anderson Cancer Center to discover novel antigens in triple-negative breast cancer for the development of innovative T-cell therapies. The award period runs from February 15, 2025 to February 14, 2028, with the ultimate goal of transforming healthcare for military service members, veterans, and the broader...
- This Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program will provide $934,501 to The Children's Hospital of Philadelphia Research Institute to develop peptide-centric chimeric antigen receptor (CAR) therapies for neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs). The award began on September 1, 2025 and is scheduled for completion by August 31, 2028. The research aims to advance...
- The Defense Health Agency awarded a $819,080 Project Grant to The University of Texas M.D. Anderson Cancer Center to evaluate how maternal dietary exposure affects neurodevelopment and cognition in neurofibromatosis type 1 (NF1) under the Military Medical Research and Development program (CFDA 12.420). The University of Texas M.D. Anderson Cancer Center will conduct research into medical solutions for the battlefield and innovative healthcare for service members and the public by investigating...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $718,858 to The University of Texas MD Anderson Cancer Center to conduct research on the "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies." The research aims to identify new cancer-related antigens that can be targeted by T-cell therapies for treating triple-negative breast...